{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:29:15Z","timestamp":1794738555892,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary adenylate cyclase-activating polypeptide (PACAP), structurally related to vasoactive intestinal peptide (VIP), is one of the important mediators in the pathogenesis of migraine and is known to dilate cranial arteries and induce headache and migraine. Our objective was to determine whether Lu\u00a0AG09222\u2014an investigational humanized monoclonal antibody directed against PACAP ligand\u2014would inhibit the PACAP-signaling cascade by abolishing its vasodilatory and headache-inducing abilities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a randomized, double-blind, parallel-group, single-dose, placebo-controlled study of Lu\u00a0AG09222, healthy volunteers aged 18\u201345\u00a0years without history of headache disorders were randomly allocated to three treatment sequences (1:2:2) on two experimental infusion visits with 9\u2009\u00b1\u20093\u00a0days\u2019 interval: placebo\u2009+\u2009saline\u2009+\u2009saline (<jats:italic>n<\/jats:italic>\u2009=\u20095), placebo\u2009+\u2009PACAP38\u2009+\u2009VIP (<jats:italic>n<\/jats:italic>\u2009=\u200910), and Lu\u00a0AG09222\u2009+\u2009PACAP38\u2009+\u2009VIP (<jats:italic>n<\/jats:italic>\u2009=\u200910). The primary outcome measure was area under the curve (AUC) of the change in superficial temporal artery (STA) diameter from 0 to 120\u00a0min after start of infusion of PACAP38. The study was conducted at the Danish Headache Center in Copenhagen, Denmark.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In participants who received Lu\u00a0AG09222\u2009+\u2009PACAP38 infusion, there was a significantly lower STA diameter (mean (SE) [95% CI] AUC \u201235.4 (4.32) [\u201244.6, \u201226.3] mm\u2009\u00d7\u2009min; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) compared to participants who received placebo\u2009+\u2009PACAP38 infusion. Secondary and explorative analysis revealed that PACAP38 infusion induced an increase in facial blood flow, heart rate and mild headache, and indicated that these PACAP38-induced responses were inhibited by Lu AG09222.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This proof-of-mechanism study demonstrated that Lu\u00a0AG09222 inhibited PACAP38-induced cephalic vasodilation and increases in heart rate, and reduced concomitant headache. Lu\u00a0AG09222 may be a potential therapy against migraine and other PACAP-mediated diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov: NCT04976309. Registration date: July 19, 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01599-w","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T09:02:44Z","timestamp":1685005364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study"],"prefix":"10.1186","volume":"24","author":[{"given":"Nadja Bredo","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper Emil","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Kristian","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar Muhsen","family":"Al-Khazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Van de Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Granhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"1599_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"1599_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"1599_CR3","first-page":"619","volume":"21","author":"NM Sherwood","year":"2000","unstructured":"Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)\/glucagon superfamily. Endocr Rev 21:619\u2013670","journal-title":"Endocr Rev"},{"key":"1599_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2008.11.006","volume":"121","author":"L Dickson","year":"2009","unstructured":"Dickson L, Finlayson K (2009) VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121:294\u2013316","journal-title":"Pharmacol Ther"},{"key":"1599_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1476-5381.2012.01871.x","volume":"166","author":"AJ Harmar","year":"2012","unstructured":"Harmar AJ, Fahrenkrug J, Gozes I et al (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4\u201317","journal-title":"Br J Pharmacol"},{"key":"1599_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP et al (2019) Migraine and the trigeminovascular system\u201440 years and counting. Lancet Neurol 18:795\u2013804","journal-title":"Lancet Neurol"},{"key":"1599_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1124\/pr.109.001370","volume":"61","author":"D Vaudry","year":"2009","unstructured":"Vaudry D, Falluel-Morel A, Bourgault S et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283\u2013357","journal-title":"Pharmacol Rev"},{"key":"1599_CR8","first-page":"269","volume":"52","author":"D Vaudry","year":"2000","unstructured":"Vaudry D, Basille M, Yon L et al (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269\u2013324","journal-title":"Pharmacol Rev"},{"key":"1599_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","volume":"164","author":"A Miyata","year":"1989","unstructured":"Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567\u2013574","journal-title":"Biochem Biophys Res Commun"},{"key":"1599_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0006-291X(90)92140-U","volume":"170","author":"A Miyata","year":"1990","unstructured":"Miyata A, Jiang L, Dahl RD et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643\u2013648","journal-title":"Biochem Biophys Res Commun"},{"key":"1599_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.regpep.2006.12.010","volume":"140","author":"S Birk","year":"2007","unstructured":"Birk S, Sitarz JT, Petersen KA et al (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140:185\u2013191","journal-title":"Regul Pept"},{"key":"1599_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","volume":"132","author":"HW Schytz","year":"2009","unstructured":"Schytz HW, Birk S, Wienecke T et al (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16\u201325","journal-title":"Brain"},{"key":"1599_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0333102411431333","volume":"32","author":"FM Amin","year":"2012","unstructured":"Amin FM, Asghar MS, Guo S et al (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32:140\u2013149","journal-title":"Cephalalgia"},{"key":"1599_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/brain\/awt369","volume":"137","author":"FM Amin","year":"2014","unstructured":"Amin FM, Hougaard A, Schytz HW et al (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779\u2013794","journal-title":"Brain"},{"key":"1599_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/0333102413483931","volume":"33","author":"B Tuka","year":"2013","unstructured":"Tuka B, Helyes Z, Markovics A et al (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33:1085\u20131095","journal-title":"Cephalalgia"},{"key":"1599_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13311-017-0596-x","volume":"15","author":"ALH Vollesen","year":"2018","unstructured":"Vollesen ALH, Amin FM, Ashina M (2018) Targeted pituitary adenylate cyclase-activating peptide therapies for migraine. Neurotherapeutics 15:371\u2013376","journal-title":"Neurotherapeutics"},{"key":"1599_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1124\/jpet.118.253443","volume":"369","author":"CM Loomis","year":"2019","unstructured":"Loomis CM, Dutzar B, Ojala EW et al (2019) Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide. J Pharmacol Exp Ther 369:26\u201336","journal-title":"J Pharmacol Exp Ther"},{"key":"1599_CR18","unstructured":"Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention - H. Lundbeck A\/S. https:\/\/news.cision.com\/h--lundbeck-a-s\/r\/lundbeck-announced-the-start-of-a-phase-ii-clinical-study-to-assess-lu-ag09222-for-migraine-preventi,c3453442. Accessed 10 Oct 2022"},{"key":"1599_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-017-0821-3","volume":"18","author":"H Ashina","year":"2017","unstructured":"Ashina H, Guo S, Vollesen ALH, Ashina M (2017) PACAP38 in human models of primary headaches. J Headache Pain 18:1\u20139","journal-title":"J Headache Pain"},{"key":"1599_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","volume":"13","author":"M Ashina","year":"2017","unstructured":"Ashina M, Hansen JM, Olesen J (2017) Human models of migraine\u2014short-term pain for long-term gain. Nat Rev Neurol 13:713\u2013724","journal-title":"Nat Rev Neurol"},{"key":"1599_CR21","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1599_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/S41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514. https:\/\/doi.org\/10.1038\/S41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"key":"1599_CR23","doi-asserted-by":"publisher","unstructured":"Guo S, Ernstsen C, Hay-Schmidt A, et al (2022) PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine. Journal of Headache and Pain 23:. https:\/\/doi.org\/10.1186\/s10194-022-01523-8","DOI":"10.1186\/s10194-022-01523-8"},{"key":"1599_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.peptides.2004.08.002","volume":"25","author":"I Jansen-Olesen","year":"2004","unstructured":"Jansen-Olesen I, Gulbenkian S, Engel U et al (2004) Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides (NY) 25:2105\u20132114","journal-title":"Peptides (NY)"},{"key":"1599_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/01.WCB.0000121234.42748.F6","volume":"24","author":"F Martin","year":"2004","unstructured":"Martin F, Baeres M, M\u00f8ller M (2004) Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain. J Cereb Blood Flow Metab 24:628\u2013635","journal-title":"J Cereb Blood Flow Metab"},{"key":"1599_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0196-9781(01)00408-9","volume":"22","author":"S Gulbenkian","year":"2001","unstructured":"Gulbenkian S, Uddman R, Edvinsson L (2001) Neuronal messengers in the human cerebral circulation. Peptides (NY) 22:995\u20131007","journal-title":"Peptides (NY)"},{"key":"1599_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00001756-200203250-00030","volume":"13","author":"M Knutsson","year":"2002","unstructured":"Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. NeuroReport 13:507\u2013509","journal-title":"NeuroReport"},{"key":"1599_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01089-3","volume":"21","author":"H Ghanizada","year":"2020","unstructured":"Ghanizada H, Al-Karagholi MA-M, Arngrim N et al (2020) Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. J Headache Pain 21:1\u201310","journal-title":"J Headache Pain"},{"key":"1599_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/0333102420975395","volume":"41","author":"NKF Wienholtz","year":"2021","unstructured":"Wienholtz NKF, Christensen CE, Zhang DG et al (2021) Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia 41:731\u2013748","journal-title":"Cephalalgia"},{"key":"1599_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0333102420970889","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Dole\u017eil D, Bonner JH et al (2021) A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41:33\u201344","journal-title":"Cephalalgia"},{"key":"1599_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0333102416639517","volume":"37","author":"S Guo","year":"2017","unstructured":"Guo S, Vollesen ALH, Hansen YBL et al (2017) Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia 37:136\u2013147. https:\/\/doi.org\/10.1177\/0333102416639517","journal-title":"Cephalalgia"},{"key":"1599_CR32","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1468-2982.2006.01149.x","volume":"26","author":"JM Hansen","year":"2006","unstructured":"Hansen JM, Sitarz J, Birk S et al (2006) Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26:992\u20131003","journal-title":"Cephalalgia"},{"key":"1599_CR33","doi-asserted-by":"publisher","first-page":"e2118543","DOI":"10.1001\/jamanetworkopen.2021.18543","volume":"4","author":"L Pellesi","year":"2021","unstructured":"Pellesi L, Al-Karagholi MA-M, De Icco R et al (2021) Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open 4:e2118543\u2013e2118543","journal-title":"JAMA Netw Open"}],"updated-by":[{"DOI":"10.1186\/s10194-023-01610-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T21:01:48Z","timestamp":1686949308000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01599-w","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-023-01610-4","URL":"https:\/\/doi.org\/10.1186\/s10194-023-01610-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was designed in accordance with the Declaration of Helsinki and conducted in compliance with Good Clinical Practice and applicable regulatory requirements; all participants provided informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Karlsson has nothing to disclose. Dr. Rasmussen is a member of the editorial group G (neuromuscular diseases) of the neurological National Treatment Guidelines, Danish Neurological Society. Dr. Deligianni was supported by an IHS research fellowship grant and serves as a board member for the European Headache Federation. Dr. Christensen has received consulting fees and lecture honoraria from Teva; serves as a board member for the Danish Headache Society; and is a member of the steering committee for the Danish National Knowledge Center for Headache. Dr. Al-Khazali serves as a board member for the Danish Headache Society. Drs. Van de Casteele and Granhall are employees of Lundbeck. Dr. Amin has received personal fees from Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; has received institutional payments from Novartis and Teva; has served on advisory boards for Pfizer, Eli Lilly, Lundbeck, Novartis and Teva; and serves as associate editor for Acta Neurologica Scandinavica, for Headache Medicine and for Frontiers in Pain Research, as junior associate editor for Cephalalgia and member of the editorial board of The Journal of Headache and Pain; is the President of Danish Headache Society and is a member of the European Headache Federation\u2019s Board of Directors. Dr. Ashina is a principal investigator on clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; has received personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; has received institutional research grants from Lundbeck Foundation, Novartis and Novo Nordisk Foundation; and serves as an Associate Editor of Cephalalgia, The Journal of Headache and Pain and Brain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}